Stuart M. Mcguigan Acquires 15,000 Shares of Enhabit, Inc. (NYSE:EHAB) Stock

Enhabit, Inc. (NYSE:EHAB) Director Stuart M. Mcguigan acquired 15,000 shares of the company’s stock in a transaction that occurred on Tuesday, December 10th. The stock was acquired at an average price of $8.81 per share, with a total value of $132,150.00. Following the acquisition, the director now directly owns 46,810 shares of the company’s stock, valued at approximately $412,396.10. This represents a 47.15 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this link.

Enhabit Stock Down 0.7 %

Shares of NYSE:EHAB traded down $0.06 on Wednesday, hitting $8.53. 283,695 shares of the company’s stock were exchanged, compared to its average volume of 574,581. The company has a debt-to-equity ratio of 0.85, a quick ratio of 1.46 and a current ratio of 1.46. The firm’s 50-day moving average is $7.50 and its 200 day moving average is $8.31. The company has a market capitalization of $428.92 million, a PE ratio of -3.70 and a beta of 1.89. Enhabit, Inc. has a 1-year low of $6.85 and a 1-year high of $11.74.

Enhabit (NYSE:EHAB) last released its quarterly earnings data on Wednesday, November 6th. The company reported $0.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by ($0.01). The company had revenue of $253.60 million during the quarter, compared to analyst estimates of $261.69 million. Enhabit had a negative net margin of 11.24% and a positive return on equity of 1.67%. During the same quarter in the prior year, the company earned $0.03 EPS. Sell-side analysts predict that Enhabit, Inc. will post 0.22 EPS for the current year.

Analysts Set New Price Targets

EHAB has been the topic of several analyst reports. Jefferies Financial Group upgraded Enhabit from a “hold” rating to a “buy” rating and increased their price objective for the company from $8.25 to $9.50 in a research note on Monday. Leerink Partners reiterated a “market perform” rating and issued a $8.00 price objective (down previously from $8.50) on shares of Enhabit in a research note on Tuesday, November 19th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and one has given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $9.40.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Jane Street Group LLC grew its stake in shares of Enhabit by 514.3% during the 3rd quarter. Jane Street Group LLC now owns 901,084 shares of the company’s stock worth $7,119,000 after purchasing an additional 754,395 shares during the period. Marshall Wace LLP acquired a new position in Enhabit during the second quarter worth about $1,941,000. Systematic Financial Management LP increased its holdings in Enhabit by 12.2% in the third quarter. Systematic Financial Management LP now owns 1,838,199 shares of the company’s stock valued at $14,522,000 after buying an additional 199,235 shares in the last quarter. DekaBank Deutsche Girozentrale lifted its position in shares of Enhabit by 52.3% during the 2nd quarter. DekaBank Deutsche Girozentrale now owns 518,412 shares of the company’s stock valued at $4,306,000 after acquiring an additional 178,000 shares during the period. Finally, Bardin Hill Management Partners LP boosted its stake in shares of Enhabit by 927.4% during the 3rd quarter. Bardin Hill Management Partners LP now owns 174,304 shares of the company’s stock worth $1,377,000 after acquiring an additional 157,338 shares in the last quarter.

About Enhabit

Enhabit, Inc provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services.